Clinical trials: malaria
Malaria, Febrile Illness
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya
Highly subsidized first-line antimalarials (artemisinin combination therapy or ACT) are available over the counter in the private retail sector in most malaria-endemic countries.
- Trial name
- NCT04428307
- Testing
- Conditional artemisinin combination therapy subsidy, Testing incentive
- Where
- Kenya
- Volunteers
- 5,696 people
- Sponsor
- Duke University
Malaria, Malaria,Falciparum
PfSPZ Vaccine Trial in Malian Children
In this randomized, double-blind, placebo-controlled trial, 268 healthy Malian children aged 6-10 years, residing in Bancoumana and surrounding villages, will be administered three doses of 9.0x10^5 Pf sporozoites (PfSPZ) of…
- Trial name
- NCT04940130
- Testing
- Sanaria® PfSPZ Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
OZ439 is a novel, synthetic trioxolane medicine which is related to artemisinin, but has the advantage of a longer elimination half-life so is being developed to be administered together with a potential partner drug e.g.
- Trial name
- NCT01615822
- Testing
- OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.
This trial aims to characterise the pharmacokinetic (PK) profile and estimate drug exposure of a single oral dose of piperaquine (PQP) in a dispersible granule formulation compared to the PQP hard tablet formulation in the fasted…
- Trial name
- PedPQP(BA/FE) (NCT05930782)
- Testing
- Piperaquine Tetraphosphate uncoated tablets, Piperaquine Tetraphosphate dispersible granules
- Where
- Tanzania
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
MMV533 Plasmodium Falciparum Volunteer Infection Study
A Phase 1b study to assess the safety, tolerability and antimalarial activity of MMV533 against Plasmodium falciparum 3D7 blood stage infection in healthy volunteers
- Trial name
- NCT05205941
- Testing
- MMV688533
- Where
- Australia
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Falciparum Parasitaemia
An Evaluation of Weekly Tafenoquine
This was a placebo controlled, randomised, double-blind, double-dummy study of the efficacy of weekly tafenoquine compared with weekly mefloquine or placebo in the chemosuppression of P.
- Trial name
- NCT02488980
- Testing
- Tafenoquine, Mefloquine
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants
This will be a double-blinded randomized controlled phase III trial of 300 HIV uninfected pregnant women and the children born to them. The study interventions will be divided into two phases.
- Trial name
- PROMOTE-BC1 (NCT02163447)
- Testing
- Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
- Where
- Uganda
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Methylene Blue Against Falciparum Malaria in Burkina Faso
Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum malaria treatment in African children: A randomised controlled trial Elimination has become the goal of malaria programmes in an…
- Trial name
- BlueACTn (NCT02851108)
- Testing
- Methylene Blue, Primaquine
- Where
- Burkina Faso
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P.
- Trial name
- NCT01954264
- Testing
- Capillary blood sample, Data collection
- Where
- 3 sites in Burkina Faso, Senegal
- Volunteers
- 2,421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Africa
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
- Trial name
- NCT01190202
- Testing
- Blood sampling, Assessment of body temperature
- Where
- 8 sites in Burkina Faso, Gabon and 4 more
- Volunteers
- 21,618 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asymptomatic Parasitemia In Pregnancy
Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa
The study will be conducted in asymptomatic pregnant women with P. falciparum parasitemia. The subjects will be given 3 day dosing regiment of the fixed-dose combination of Azithromycin and Chloroquine.
- Trial name
- NCT01103713
- Testing
- Azithromycin plus chloroquine
- Where
- 7 sites in Benin, Kenya and 3 more
- Volunteers
- 168 people
- Sponsor
- Pfizer
Malaria,Falciparum, Child, Only
Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study
A double-blind, individual randomised trial will be undertaken in children under five years of age living in areas of Burkina Faso or Mali where the transmission of malaria is intense and highly seasonal to determine whether…
- Trial name
- RTSS-SMC (NCT04319380)
- Testing
- Tetanus/diphtheria toxoids, SMC with SP+AQ, RTS,S/AS01
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 5,098 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
The purpose of this pre-licensure cohort study was to estimate the incidence of adverse events of special interest (AESI), other adverse events (AE) leading to hospitalisation or death, meningitis and malaria in sub-Saharan…
- Trial name
- NCT02374450
- Testing
- Blood collection
- Where
- 5 sites in Burkina Faso, Ghana and 1 more
- Volunteers
- 36,366 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug-Drug Interaction, HIV Infection
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART)…
- Trial name
- DPART (NCT04487145)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Infection, Malaria
L9LS MAb in Malian Adults
The purpose of this study is to evaluate the safety and tolerability of a one time SC administration of L9LS in healthy adults in Mali, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf)…
- Trial name
- NCT05816330
- Testing
- L9LS (VRC-MALMAB0114-00-AB)
- Where
- 3 sites in Mali
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
A single centre, open, controlled study using Blood Stage Plasmodium falciparum challenge inoculum (BSPC) as a model to assess the effectiveness of three dose levels of the experimental anti-malarial product, OZ439.
- Trial name
- NCT02453581
- Testing
- OZ439
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford